353 related articles for article (PubMed ID: 33692755)
1. Whole Genome Sequencing Prioritizes
Srivastava A; Giangiobbe S; Skopelitou D; Miao B; Paramasivam N; Diquigiovanni C; Bonora E; Hemminki K; Försti A; Bandapalli OR
Front Endocrinol (Lausanne); 2021; 12():600682. PubMed ID: 33692755
[TBL] [Abstract][Full Text] [Related]
2. Identification of Rare Variants Predisposing to Thyroid Cancer.
Wang Y; Liyanarachchi S; Miller KE; Nieminen TT; Comiskey DF; Li W; Brock P; Symer DE; Akagi K; DeLap KE; He H; Koboldt DC; de la Chapelle A
Thyroid; 2019 Jul; 29(7):946-955. PubMed ID: 30957677
[No Abstract] [Full Text] [Related]
3. Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways.
Srivastava A; Kumar A; Giangiobbe S; Bonora E; Hemminki K; Försti A; Bandapalli OR
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31614935
[TBL] [Abstract][Full Text] [Related]
4.
Brock P; Liynarachchi S; Nieminen TT; Chan C; Kohlmann W; Stout LA; Yao S; La Greca A; Jensen KE; Kolesar JM; Salhia B; Gulhati P; Hicks JK; Ringel MD
Thyroid; 2024 Apr; 34(4):477-483. PubMed ID: 38279823
[No Abstract] [Full Text] [Related]
5. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
6. A Germline
Zhao Y; Yu T; Chen L; Xie D; Wang F; Fu L; Cheng C; Li Y; Zhu X; Miao G
Thyroid; 2020 Jun; 30(6):924-930. PubMed ID: 32041497
[TBL] [Abstract][Full Text] [Related]
7. HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.
Alzahrani AS; Murugan AK; Qasem E; Al-Hindi H
Thyroid; 2016 May; 26(5):667-71. PubMed ID: 26906432
[TBL] [Abstract][Full Text] [Related]
8. Germline mutations in a DNA repair pathway are associated with familial colorectal cancer.
Xu P; Sun D; Gao Y; Jiang Y; Zhong M; Zhao G; Chen J; Wang Z; Liu Q; Hong J; Chen H; Chen YX; Fang JY
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549727
[TBL] [Abstract][Full Text] [Related]
9. Identification of Familial Hodgkin Lymphoma Predisposing Genes Using Whole Genome Sequencing.
Srivastava A; Giangiobbe S; Kumar A; Paramasivam N; Dymerska D; Behnisch W; Witzens-Harig M; Lubinski J; Hemminki K; Försti A; Bandapalli OR
Front Bioeng Biotechnol; 2020; 8():179. PubMed ID: 32211398
[TBL] [Abstract][Full Text] [Related]
10. A Germline Mutation in the
Srivastava A; Miao B; Skopelitou D; Kumar V; Kumar A; Paramasivam N; Bonora E; Hemminki K; Försti A; Bandapalli OR
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32492864
[TBL] [Abstract][Full Text] [Related]
11. Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.
Zhou J; Singh P; Yin K; Wang J; Bao Y; Wu M; Pathak K; McKinley SK; Braun D; Lubitz CC; Hughes KS
Ann Surg Oncol; 2021 Oct; 28(11):6590-6600. PubMed ID: 33660127
[TBL] [Abstract][Full Text] [Related]
12. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
13. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
14. Familial Cancer Variant Prioritization Pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family.
Kumar A; Bandapalli OR; Paramasivam N; Giangiobbe S; Diquigiovanni C; Bonora E; Eils R; Schlesner M; Hemminki K; Försti A
Sci Rep; 2018 Aug; 8(1):11635. PubMed ID: 30072699
[TBL] [Abstract][Full Text] [Related]
15. A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.
Pires C; Marques IJ; Dias D; Saramago A; Leite V; Cavaco BM
Endocrine; 2021 Sep; 73(3):588-597. PubMed ID: 33683595
[TBL] [Abstract][Full Text] [Related]
16.
Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
[TBL] [Abstract][Full Text] [Related]
17. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline
Thibodeau ML; Reisle C; Zhao E; Martin LA; Alwelaie Y; Mungall KL; Ch'ng C; Thomas R; Ng T; Yip S; J Lim H; Sun S; Young SS; Karsan A; Zhao Y; Mungall AJ; Moore RA; J Renouf D; Gelmon K; Ma YP; Hayes M; Laskin J; Marra MA; Schrader KA; Jones SJM
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28514723
[TBL] [Abstract][Full Text] [Related]
18. Genetic susceptibility to hereditary non-medullary thyroid cancer.
Kamani T; Charkhchi P; Zahedi A; Akbari MR
Hered Cancer Clin Pract; 2022 Mar; 20(1):9. PubMed ID: 35255942
[TBL] [Abstract][Full Text] [Related]
19. Clinically-relevant Germline Variants in Children with Non-Medullary Thyroid Cancer.
van der Tuin K; Ruano D; Knijnenburg J; van der Luijt RB; Morreau H; Links TP; Hes FJ;
J Clin Endocrinol Metab; 2024 Feb; ():. PubMed ID: 38415346
[TBL] [Abstract][Full Text] [Related]
20. Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients.
Capezzone M; Sagnella A; Cantara S; Fralassi N; Maino F; Forleo R; Brilli L; Pilli T; Cartocci A; Castagna MG
Front Endocrinol (Lausanne); 2022; 13():845954. PubMed ID: 35311228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
